The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy.
OBJECTIVE
To investigate the effects of salpingectomy and methotrexate treatments on ovarian reserve in ectopic pregnancy.


METHODS
In this prospective study, a total of 131 patients with ectopic pregnancy were divided into 3 groups of methotrexate (MTX) only (Group-1, n: 55), salpingectomy only (Group-2, n: 61), and salpingectomy following MTX (Group-3, n: 15). Pretreatment and post-treatment anti-Müllerian hormone (AMH) levels were evaluated.


RESULTS
Significant differences in AMH levels were detected between group 1 and group 2 (2.52±1.28 vs. 1.96±1.66, p=0.043), and group 1 and group 3 (2.52±1.28 vs. 1.77±0.76, p=0.035) at one month postoperative. However, these differences disappeared at the 3rd postoperative month. When AMH levels were compared within the same group, postoperative one month AMH levels were significantly lower than the preoperative AMH levels only in group 3 (p=0.03). However, this difference also disappeared at the 3rd postoperative month.


CONCLUSIONS
Systemic single-dose methotrexate treatment, unilateral salpingectomy, and salpingectomy following methotrexate administration in ectopic pregnancy were reassuring based on pretreatment and post-treatment AMH levels. Current medical and surgical treatment approaches do not have an obvious negative effect on ovarian reserve.
Ege University School of Medicine, Department of Obstetrics and Gynecology, Bornova, Izmir, Turkey.
Cagdas
C
Sahin
Ege University School of Medicine, Department of Obstetrics and Gynecology, Bornova, Izmir, Turkey. Electronic address: enestaylanmd@gmail.com.
Enes
E
Taylan
Ege University School of Medicine, Department of Obstetrics and Gynecology, Bornova, Izmir, Turkey.
Ali
A
Akdemir
Yasar University School of Science and Letter, Department of Actuarial, Bornova, Izmir, Turkey.
Banu
B
Ozgurel
Ege University School of Medicine, Department of Physiology, Bornova, Izmir, Turkey.
Dilek
D
Taskıran
Ege University School of Medicine, Department of Obstetrics and Gynecology, Bornova, Izmir, Turkey.
Ahmet M
AM
Ergenoglu
D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use*; D065851:Ovarian Reserve / Q000187:drug effects*; D010053:Ovary / Q000187:drug effects; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011446:Prospective Studies; D058994:Salpingectomy; D016896:Treatment Outcome; D055815:Young Adult
D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate
Ectopic pregnancy; Methotrexate; Ovarian reserve; Salpingectomy